Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis
P K Lorgelly1, M Atkinson, M Lakhanpaul
1Section of Public Health and Health Policy, University of Glasgow, Glasgow, UK. paula.lorgelly@buseco.monash.edu.au
Insights
Oral amoxicillin is a cost-effective treatment for pediatric community-acquired pneumonia. This approach minimizes healthcare costs compared to intravenous antibiotics, offering significant savings per child.
Area of Science:
- Pediatric infectious diseases
- Health economics
- Pharmacoeconomics
Background:
- Community-acquired pneumonia (CAP) imposes a significant financial burden on healthcare systems.
- Effective and cost-efficient treatment strategies for pediatric CAP are crucial for resource optimization.
Purpose of the Study:
- To estimate and compare the costs of treating pediatric CAP using oral amoxicillin versus intravenous benzyl penicillin.
- To determine the cost-minimizing antibiotic treatment strategy for hospitalized children with CAP.
Main Methods:
- A cost-minimization analysis was conducted alongside a randomized controlled non-blinded equivalence trial.
- 232 children with pneumonia requiring hospitalization were randomized to receive either oral amoxicillin or intravenous benzyl penicillin.
- The analysis encompassed costs to the health service, patients, and society from pre-admission to full recovery.
Main Results:
- Both oral amoxicillin and intravenous benzyl penicillin demonstrated equivalent efficacy.
- Children receiving intravenous antibiotics had significantly longer in-patient stays (3.12 vs. 1.93 days).
- Intravenous treatment was substantially more expensive ( £1,256 vs. £769 per child), with savings of £473-£518 per child favoring oral amoxicillin.
Conclusions:
- Oral amoxicillin represents a cost-effective treatment for the majority of children hospitalized with community-acquired pneumonia.
- Switching from intravenous to oral antibiotic treatment can lead to significant cost savings for healthcare providers.
- This study supports the use of oral amoxicillin as a primary treatment modality for pediatric CAP to reduce healthcare expenditures.
Abstract:
Community-acquired pneumonia represents a high financial burden to healthcare providers. This manuscript seeks to estimate and compare the costs of treating children hospitalised with community-acquired pneumonia, with oral and intravenous antibiotics, thus determining which treatment is cost minimising. A cost-minimisation analysis was undertaken alongside a randomised controlled non-blinded equivalence trial. 232 children (from eight paediatric centres in England) diagnosed with pneumonia, who required admission to hospital, were randomised to receive oral amoxicillin or i.v. benzyl penicillin. The analysis considered the cost to the health service, patients and society, from pre-admission until the child was fully recovered. Oral amoxicillin and i.v. benzyl penicillin have equivalent efficacy. Children treated with i.v. antibiotics were found to have significantly longer in-patient stays (3.12 versus 1.93 days; p<0.001). i.v. treatment was found to be more expensive than oral treatment ( pound1,256 versus pound769; difference pound488; 95% CI: pound233- pound750), such that treatment of community-acquired pneumonia with oral amoxicillin would result in savings of between pound473 and pound518 per child (euro545 and euro596 per child) admitted. The findings demonstrate that oral amoxicillin is a cost-effective treatment for the majority of children admitted to hospital with pneumonia.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Dosage Interval and Administration Route: Determination Methods
Drug Dosing: Infants and Children
Acute Pyelonephritis II: Diagnostic Studies and Management
